GlassScriptPhysician profile
Ghasoub Harb
NPI 1356344287
$14,230.85
in general payments reported to CMS, 2019-2025
28 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,200 · 2020: $1,153 · 2021: $1,758 · 2022: $726 · 2023: $338 · 2024: $670 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.69 |
| Education | $444.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,610.27 | 2019-2024 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $2,709.70 | 2019-2024 | |
| Neotract INC. | $1,913.19 | 2019-2020 | |
| Accord Healthcare, INC. | $762.65 | 2021 | |
| Astellas Pharma US INC | $371.53 | 2022-2024 | Xtandi |
| Teleflex LLC | $264.87 | 2021-2022 | |
| Pfizer INC. | $245.71 | 2022-2025 | |
| Tosoh Bioscience, INC. | $239.00 | 2019 | |
| Dendreon Pharmaceuticals LLC | $215.50 | 2022-2024 | Provenge |
| Tolmar, INC. | $120.26 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $120.26 | 2025 | Rubraca |
| Stryker Corporation | $115.38 | 2019 | |
| Sumitomo Pharma America, INC. | $107.73 | 2025 | Orgovyx |
| Coloplast Corp | $72.96 | 2021 | |
| Abbvie INC. | $68.59 | 2020-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $55.77 | 2023 | Prolaris, Precisetumor |
| Valencia Technologies Corporation | $40.54 | 2022 | |
| Isoray, INC | $34.65 | 2020 | |
| Sun Pharmaceutical Industries INC. | $23.75 | 2024 | |
| Merck Sharp & Dohme LLC | $23.48 | 2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $17.92 | 2022 | |
| Dornier Medtech America, INC | $17.86 | 2019 | |
| Progenics Pharmaceuticals, INC. | $17.69 | 2023 | Pylarify |
| Boston Scientific Corporation | $16.92 | 2024 | Advance Xp |
| Amgen INC. | $15.54 | 2022 | |
| Myovant Sciences INC. | $15.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $12.63 | 2019 | |
| Ambu INC. | $1.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghasoub Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.